准脂肪组织功能保护心力衰竭与保存的喷射分数保护
Jordan Jousma1, Zhenbo Han1, Jooman Park2
1Department of Pharmacology & Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL, 60612, USA.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|November 24, 2025
概括
准热源性脂肪组织 (AT) 改善了与肥胖有关的心力衰竭与保存的射出分数 (HFpEF) 的心脏功能. 激活或增强热源性AT为心脏代谢健康提供了一个有前途的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 代谢健康 代谢健康
- 脂肪组织生物学 脂肪组织生物学
背景情况:
- 肥胖是心力衰竭的主要危险因素之一,心力衰竭的危险因素包括心力衰竭与保存的喷射分数 (HFpEF).
- 热源性脂肪组织 (AT) 在与肥胖相关的HFpEF中的作用尚不清楚.
- 了解脂肪心轴对于开发新的治疗策略至关重要.
研究的目的:
- 调查如何准热源性脂肪组织 (AT) 在心力衰竭模型中影响心脏功能,以保留射出分数 (HFpEF).
- 评估药物学,手术和基因干预对热源性AT和心脏结局的影响.
- 阐明连接AT热生成和心脏健康的潜在机制.
主要方法:
- 使用了一个"双击"的HFpEF鼠标模型.
- 使用β3-上腺素受体激动剂CL-316,243 (CL) 激活热原性AT.
- 采用基因操纵 (Adipoq-Cre; Prdm16和Ucp1-Cre; Cdkn2a) 来抑制或增强AT热生成.
- 进行了脂质组分析 (LC/MS-MS),以评估心脏脂质谱.
- 进行了AT移植实验.
主要成果:
- 通过CL激活热源性AT改善了心脏功能,并减少了HFpEF诱导的心脏重塑.
- 随着热原性AT激活,观察到增加的能量消耗.
- 从CL治疗小鼠中移植的AT给予了心脏保护.
- 基因抑制热生成取消了CL的有益作用.
- 热生成AT的遗传增强改善了心脏结构和功能.
- 在AT热生成显著改变心脏脂质组.
结论:
- 在与肥胖相关的HFpEF的背景下,热源性脂肪组织在调解心脏功能方面发挥着关键作用.
- 准脂肪心轴,特别是增强AT热生成,代表了与肥胖相关的HFpEF的可行的治疗方法.
- 心脏脂质组的变化与AT热生成对心脏健康的好处有机械联系.
相关概念视频
01:30Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
01:29Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:22Heart Failure Drugs: β-Blockers
741
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
741
01:22Heart Failure Drugs: Diuretics
775
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
775